Author

E. C. Chen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Research Focus:host-pathogen & immune response· 4 Assay:proteomics· 3 Research Focus:cell type annotation· 2 Approach:statistical model· 2 Research Focus:cell-cell communication· 1 Assay:CITE-seq· 1

Frequent Co-Authors

E. Binshtein· 6 shared J. E. Crowe· 6 shared P. Gilchuk· 6 shared R. H. Carnahan· 5 shared A. Trivette· 4 shared L. Myers· 4 shared N. Suryadevara· 4 shared R. E. Sutton· 4 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

E. Binshtein

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Systematic analysis of human antibody response to ebolavirus glycoprotein reveals high prevalence of neutralizing public clonotypes

E. C. Chen, P. Gilchuk, S. J. Zost, P. A. Ilinykh, E. Binshtein, K. Huang, L. Myers, S. Bonissone, S. Day, C. R. Kona, A. Trivette, J. X. Reidy, R. E. Sutton, C. Gainza, S. Monroig, , J. E. Crowe

The paper analyzes the human antibody response to ebolavirus glycoprotein, identifying public clonotypes with neutralizing activity and implications for vaccine design.

bioRxiv · Jan 12, 2022 · PreprintImmunology

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals

E. C. Chen, P. Gilchuk, S. J. Zost, N. Suryadevara, E. S. Winkler, C. R. Cabel, E. Binshtein, R. E. Sutton, J. L. Rodriguez, S. Day, L. Myers, A. Trivette, J. K. Williams, E. Davidson, S. Li, , J. E. Crowe

The paper identifies public antibody clonotypes in SARS-CoV-2 convalescents and vaccinated individuals, revealing common epitope recognition and potential vaccine efficacy mechanisms.

bioRxiv · May 2, 2021Immunology

Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail

J. Dong, S. Zost, A. Greaney, T. N. Starr, A. S. Dingens, E. C. Chen, R. Chen, B. Case, R. Sutton, P. Gilchuk, J. Rodriguez, E. Armstrong, C. Gainza, R. Nargi, E. Binshtein, , J. E. Crowe

This paper determines the structures of two antibodies in the AZD7442 cocktail that neutralize SARS-CoV-2 and identifies critical residues for neutralization and viral escape.

bioRxiv · Jan 27, 2021 · PreprintImmunology

Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein

N. Suryadevara, S. Shrihari, P. Gilchuk, L. VanBlargan, E. Binshtein, S. Zost, R. Nargi, R. Sutton, E. S. Winkler, E. C. Chen, M. E. Fouch, E. Davidson, B. Doranz, R. H. Carnahan, L. Thackray, , J. E. Crowe

The paper identifies two NTD-specific human mAbs with neutralizing activity against SARS-CoV-2 and shows they require Fc effector functions for optimal protection.

bioRxiv · Jan 19, 2021Immunology

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

S. J. Zost, P. Gilchuk, J. B. Case, E. Binshtein, R. E. Chen, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, L. E. Williamson, E. C. Chen, T. Jones, S. Day, L. Myers, , J. E. Crowe

The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.

bioRxiv · May 22, 2020Immunology

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

S. J. Zost, P. Gilchuk, R. Chen, J. B. Case, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, E. C. Chen, E. Binshtein, S. Shrihari, M. A. Ostrowski, H. Y. Chu, J. E. Didier, , J. E. Crowe

This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.

bioRxiv · May 12, 2020Immunology